Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael

Showing results (1051-1060 of 1,111) with videos related to

Pageof 112
Sort By:
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Annals of Internal Medicine|November 6, 2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient dataJ P Ioannidis, P S Rosenberg, J J Goedert, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Pageof 112

Showing results (1051-1060 of 1,111) with videos related to

Sort By:
Pageof 112
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Annals of Internal Medicine|November 6, 2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient dataJ P Ioannidis, P S Rosenberg, J J Goedert, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Pageof 112